Commit celebrates the new year with a seed investment from Novo Holdings (Denmark) and Bioqube Ventures (Belgium). The investment allows Commit to set the foundations of the BiCE™ platform.
More news
August 28 – 2023
Krishna Polu is appointed CEO of Commit Biologics. Krishna brings a wealth of operating experience to the team with a track record of pipeline advancement and drug approvals across multiple therapeutics areas. Most recently, …
June 28 – 2023
A joint collaboration between researchers from Commit Biologics, Christian-Albrechts-University in Kiel and Aarhus University has led to a better understanding of the complement system. The complement system plays a vital role in immune defenses. …
February 8 – 2023
Commit welcomes Anker Lundemose as executive chairman of the board. MD, PhD Anker Lundemose is CEO at Mission Therapeutics (backed by Sofinnova Partners, Roche Venture Fund, Pfizer Ventures and SR One) and has held …
For inquiries please contact us
at info@commitbio.com
Commit Biologics ApS
Universitetsbyen 83
8000 Aarhus C, Denmark
© 2022 Commit Biologics. All rights reserved.
